Home › Research › Clinical safety
Brexpiprazole for treating agitation in different groups of people with Alzheimer’s dementia: a plain language summary
Jared Stroud, Jeffrey L. Cummings, Sanjeda R Chumki, Pedro Such, David Wang, Anton M. Palma, Z. Zhang, George Thomas Grossberg. Neurodegenerative Disease Management, 2026-02-14
Topic: Amyloid, tau and blood-test diagnosis
Plain Language SummaryWhat is this summary about?Alzheimer’s dementia is a brain disorder in which people have a gradual decline of their thinking, memory, and behavior. Many people with Alzheimer’s dementia have agitation, which includes restlessness, repetitive questions, wandering, shouting, swearing, kicking, and more.People with Alzheimer’s dementia may differ from one another. For example, people may live at home, in nursing homes, or elsewhere. Some people have mild difficulty with thinking and memory while others have more severe difficulty. People may also have other symptoms besides agitation, and may be taking different medications.Clinical studies show that a medication called brexpiprazole can improve agitation in people with Alzheimer’s dementia. In this summary, researchers combined information from two clinical studies to look at the effects of brexpiprazole in 13 different groups of people with Alzheimer’s dementia.What are the key takeaways?Brexpiprazole reduced agitation in almost all groups of people compared to placebo. This included people living at home or in a nursing home, with milder or more severe difficulty with thinking and memory, with other symptoms besides agitation, and taking some other medications. There were no clear differences in side effects across the different groups of people.What are the main conclusions reported by the researchers?These results show that brexpiprazole may help many different groups of people with agitation in Alzheimer’s dementia. This information can help doctors, caregivers, and people with dementia to make informed treatment choices.Clinical trial number: NCT01862640,NCT03548584
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Stroud, J., Cummings, J. L., Chumki, S. R., Such, P., Wang, D., Palma, A. M., et al. (2026). Brexpiprazole for treating agitation in different groups of people with Alzheimer’s dementia: a plain language summary. Neurodegenerative Disease Management. https://doi.org/10.1080/17582024.2026.2623968
Vancouver
Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, et al. Brexpiprazole for treating agitation in different groups of people with Alzheimer’s dementia: a plain language summary. Neurodegenerative Disease Management. 2026. doi:10.1080/17582024.2026.2623968. PMID: 41689409.
BibTeX
@article{stroud2026-41689409,
author = {Stroud, Jared and Cummings, Jeffrey L. and Chumki, Sanjeda R and Such, Pedro and Wang, David and Palma, Anton M. and Zhang, Z. and Grossberg, George Thomas},
title = {{Brexpiprazole for treating agitation in different groups of people with Alzheimer’s dementia: a plain language summary}},
journal = {Neurodegenerative Disease Management},
year = {2026},
doi = {10.1080/17582024.2026.2623968},
pmid = {41689409},
url = {https://doi.org/10.1080/17582024.2026.2623968}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- In this summary, researchers combined information from two clinical studies to look at the effects of brexpiprazole in 13 different groups of people with Alzheimer’s dementia.What are the key takeaways?Brexpiprazole reduced agitation in almost all groups of people compared to placebo.
- There were no clear differences in side effects across the different groups of people.What are the main conclusions reported by the researchers?These results show that brexpiprazole may help many different groups of people with agitation in Alzheimer’s dementia.
Why it matters
This plain language summary reports that brexpiprazole reduced agitation in almost all groups of people with Alzheimer's dementia compared to placebo, with no clear differences in side effects across groups. It addresses a treatment for agitation, a symptom of the disease, rather than a cure or prevention.
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurodegenerative Disease Management) |
| Journal's citation record | 0 / 4 | Neurodegenerative Disease Management: journal h-index 47 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author George Thomas Grossberg: h-index 58 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Saint Louis University: institution h-index 567 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41689409) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1080/17582024.2026.2623968
- PubMed: 41689409
- Original source →
- Free full text: Neurodegenerative Disease Management →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical safety
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.